Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting CDK7 in oncology: The avenue forward
Zhimei Li, Guan Liu, Ya Gao, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108229-108229
Closed Access | Times Cited: 20

Showing 20 citing articles:

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
Lanshu Xiao, Yi Liu, Hui Chen, et al.
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 24
Systematic literature review reveals suboptimal use of chemical probes in cell-based biomedical research
Jayden Sterling, Jennifer R. Baker, Adam McCluskey, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
CDK7 in breast cancer: mechanisms of action and therapeutic potential
Ying Gong, Huiping Li
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)
Markéta Kovalová, Joseph Peter Baraka, Václav Mik, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 2, pp. 67-87
Open Access | Times Cited: 12
The multiple functions and mechanisms of long non-coding RNAs in regulating breast cancer progression
Yongsheng Zhang, Yanjiao Xu, Yanping Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer Therapy
Mohammed Alrouji, Mohammed S. Alshammari, Saleha Anwar, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1554-1554
Open Access
Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors
Hongjin Zhang, Guohao Lin, Suyun Jia, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107456-107456
Closed Access | Times Cited: 3
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors
Fei Zhu, Zheng Lu, Wenjing Tang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 8, pp. e009869-e009869
Open Access | Times Cited: 3
Orally bioavailable styryl derivative of rohitukine-N-oxide inhibits CDK9/T1 and the growth of pancreatic cancer cells
Deendyal Bhurta, Md Mehedi Hossain, Mahir Bhardwaj, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115533-115533
Closed Access | Times Cited: 8
Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7
Hongjin Zhang, Guohao Lin, Suyun Jia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115955-115955
Closed Access | Times Cited: 6
Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy
Mingming Zheng, Xiaoyu Zhang, Weijiao Chen, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 4, pp. 369-388
Closed Access | Times Cited: 2
The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations
Mahjabin Khan, Sze Kwan Lam, Sheng Yan, et al.
Journal of Cancer Research and Therapeutics (2024) Vol. 20, Iss. 4, pp. 1224-1231
Open Access | Times Cited: 2
Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity
Yaoguang Huang, Wenwu Liu, Changhao Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116547-116547
Closed Access | Times Cited: 1
Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7)
Wenzhi Ji, Guangyan Du, Jie Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116613-116613
Closed Access | Times Cited: 1
Global trends and topics in CDK7 inhibitor research: a bibliometric analysis
Jiamin Liu, Ling He, Wenjing Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Super‐Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription‐Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer
Siyuan Yan, Zhaonan Liu, Teng Wang, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
Yilan Yang, Jiatao Liao, Zhe Pan, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
Activation of the CDK7 Gene, Coding for the Catalytic Subunit of the Cyclin-Dependent Kinase (CDK)-Activating Kinase (CAK) and General Transcription Factor II H, by the Trans-Activator Protein Tax of Human T-Cell Leukemia Virus Type-1
Mashiro Shirasawa, Rinka Nakajima, Yaxuan Zhou, et al.
Genes (2024) Vol. 15, Iss. 8, pp. 1080-1080
Open Access
A Robust Computational Framework for the Optimization of CDK7 Inhibitors as Promising Cancer Therapy
Zhaoqi Shi, Xufan Gao, Damiano Buratto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Transcriptomic Approaches in Studies on and Applications of Chimeric Antigen Receptor T Cells
Karolina Pierzynowska, Lidia Gaffke, Jan Maciej Zaucha, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1107-1107
Open Access
Page 1

Scroll to top